GlassScriptPhysician profile
Klaudiya Ruvinsky
NPI 1649275918
$7,579.24
in general payments reported to CMS, 2019-2025
38 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,183 · 2020: $1,856 · 2021: $1,988 · 2022: $1,528 · 2023: $24.60.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $24.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $24.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $886.65 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $565.23 | 2019-2022 | |
| Novo Nordisk INC | $491.90 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $452.07 | 2021-2022 | |
| Glaxosmithkline, LLC. | $433.49 | 2019-2022 | |
| Amarin Pharma, INC. | $384.55 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $370.89 | 2019-2022 | |
| Amgen INC. | $334.93 | 2019-2020 | |
| Allergan, INC. | $311.14 | 2019-2020 | |
| Pfizer INC. | $270.96 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $263.35 | 2019-2020 | |
| Horizon Therapeutics Plc | $228.04 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $227.75 | 2019-2021 | |
| Lilly USA, LLC | $223.19 | 2019-2022 | |
| Arbor Pharmaceuticals, INC. | $218.47 | 2019-2022 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $209.96 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $205.61 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $194.94 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $190.01 | 2019-2021 | |
| Genzyme Corporation | $169.97 | 2022 | |
| Nestle Healthcare Nutrition INC. | $161.77 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $143.37 | 2021-2022 | |
| Astellas Pharma US INC | $140.27 | 2019 | |
| Celgene Corporation | $113.76 | 2019 | |
| Endo Pharmaceuticals INC. | $41.81 | 2020 | |
| Ironwood Pharmaceuticals, INC | $41.70 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $40.63 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $38.04 | 2022 | |
| Vivus LLC | $34.28 | 2021 | |
| Mallinckrodt Hospital Products INC. | $26.72 | 2020 | |
| Radius Health, INC. | $26.70 | 2019 | |
| Althera Pharmaceuticals LLC | $26.54 | 2021 | |
| Amneal Pharmaceuticals LLC | $21.56 | 2021 | |
| Sobi, INC | $21.09 | 2020 | |
| Sanofi-Aventis U.S. LLC | $20.70 | 2020 | |
| Melinta Therapeutics, LLC | $20.35 | 2019 | |
| Vistapharm, INC. | $15.00 | 2021 | |
| Gilead Sciences, INC. | $11.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Klaudiya Ruvinsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.